Skip to main content

Yesterday, March 14, 2016, 82 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $5.92 to $72,390,000.00.

Highlighted Stocks Traded by Insiders:

LHC Group (LHCG) - FREE Research Report

Stelly Donald Dwayne, who is President & COO at LHC Group, sold 12,952 shares at $35.51 on March 14, 2016. Following this transaction, the President & COO owned 96,764 shares meaning that the stake was reduced by 11.81% with the 12,952-share transaction.

The shares most recently traded at $35.33, down $0.18, or 0.51% since the insider transaction. Historical insider transactions for LHC Group go as follows:

  • 4-Week # shares sold: 1,695
  • 12-Week # shares sold: 1,695
  • 24-Week # shares sold: 16,285

The average volume for LHC Group has been 134,600 shares per day over the past 30 days. LHC Group has a market cap of $648.6 million and is part of the health care sector and health services industry. Shares are down 21.15% year-to-date as of the close of trading on Monday.

LHC Group, Inc., together with its subsidiaries, provides post-acute continuum of care primarily for Medicare beneficiaries in the United States. The company operates through four segments: Home Health Services, Hospice Services, Community-Based Services, and Facility-Based Services. The company has a P/E ratio of 72.2. Currently, there are 5 analysts who rate LHC Group a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on LHCG - FREE

TheStreet Quant Ratings

rates LHC Group as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, impressive record of earnings per share growth, compelling growth in net income and good cash flow from operations. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full

LHC Group Ratings Report

TheStreet Recommends

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Innophos Holdings (IPHS) - FREE Research Report

Zatta Robert J, who is Director at Innophos Holdings, bought 2,000 shares at $28.27 on March 14, 2016. Following this transaction, the Director owned 2,000 shares meaning that the stake was boosted by 100% with the 2,000-share transaction.

The shares most recently traded at $27.84, down $0.43, or 1.54% since the insider transaction. Historical insider transactions for Innophos Holdings go as follows:

  • 4-Week # shares bought: 10,000
  • 4-Week # shares sold: 7,000
  • 12-Week # shares bought: 10,000
  • 12-Week # shares sold: 7,000
  • 24-Week # shares bought: 10,000
  • 24-Week # shares sold: 7,000

The average volume for Innophos Holdings has been 217,600 shares per day over the past 30 days. Innophos Holdings has a market cap of $545.5 million and is part of the basic materials sector and chemicals industry. Shares are down 5.8% year-to-date as of the close of trading on Monday.

Innophos Holdings, Inc., through its subsidiaries, produces performance-critical and nutritional specialty ingredients with applications in food, beverage, dietary supplements, pharmaceutical, oral care, and industrial end markets. The stock currently has a dividend yield of 6.79%. The company has a P/E ratio of 21.9. Currently, there are no analysts who rate Innophos Holdings a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on IPHS - FREE

TheStreet Quant Ratings

rates Innophos Holdings as a

hold

. The company's strengths can be seen in multiple areas, such as its good cash flow from operations and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself, deteriorating net income and disappointing return on equity. Get the full

Innophos Holdings Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Teligent (TLGT) - FREE Research Report

Grenfell-Gardner Jason, who is President & CEO at Teligent, bought 10,500 shares at $4.82 on March 14, 2016. Following this transaction, the President & CEO owned 250,207 shares meaning that the stake was boosted by 4.38% with the 10,500-share transaction.

The shares most recently traded at $5.00, up $0.18, or 3.56% since the insider transaction. Historical insider transactions for Teligent go as follows:

  • 12-Week # shares sold: 84,048
  • 24-Week # shares sold: 84,048

The average volume for Teligent has been 353,200 shares per day over the past 30 days. Teligent has a market cap of $260.1 million and is part of the health care sector and drugs industry. Shares are down 39.66% year-to-date as of the close of trading on Monday.

Teligent, Inc., a specialty generic pharmaceutical company, develops, manufactures, and markets topical formulations in the United States. It sells generic pharmaceutical products in topical, injectable, complex, and ophthalmic dosage forms under IGI label. The company has a P/E ratio of 61.5. Currently, there are 2 analysts who rate Teligent a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on TLGT - FREE

TheStreet Quant Ratings

rates Teligent as a

hold

. Among the primary strengths of the company is its expanding profit margins over time. At the same time, however, we also find weaknesses including unimpressive growth in net income, disappointing return on equity and weak operating cash flow. Get the full

Teligent Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.